

Pyrimidine-based fluorescent COX-2 inhibitors: Synthesis and biological evaluation

Ole Tietz^{a,1} Jatinder Kaur^{a,b,1} Atul Bhardwaj^{a,b}; Frank R. Wuest^{*a,b}


^aDepartment of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, T6G 1Z2, Edmonton, AB, Canada.

^bDepartment of Pharmacy and Pharmaceutical Sciences, Medical Sciences Building, University of Alberta, T6G 2H1, Edmonton, AB, Canada.


Supporting Information

1. ¹H-NMR spectra of compound **4**, **5**, **6**, **7**, **8** and **10**
2. ¹³C-NMR spectra of compound **5**, **6**, **7**, **8** and **10**


$^1\text{H-NMR}$ spectra of compound 4




¹H-NMR spectra of compound 5




¹H-NMR spectra of compound 6




¹H-NMR spectra of compound 7




¹H-NMR spectra of compound **8**




¹H-NMR spectra of compound **10**




¹³C NMR spectra of compound 5




¹³C NMR spectra of compound 6



¹³C NMR spectra of compound 7



¹³C NMR spectra of compound 8



¹³C NMR spectra of compound 10

